AGR2 and neoplasm: While dysregulation of oncogenic and tumor-suppressive pathways, such as KRAS activation and TP53 inactivation, has been extensively studied, emerging players like Anterior Gradient 2 (AGR2) are gaining attention for their roles in shaping PDAC biology [2–4].